Characterizing the Immune System After Long-Term Undetectable Viral Load in HIV-1-Infected Children

被引:0
作者
Salvador Resino
Isabel Galán
José Ma Bellón
Ma Luisa Navarro
Juan Antonio León
Ma Ángeles Muñoz-Fernández
机构
[1] Hospital General Universitario “Gregorio Marañón,Laboratorio de Inmuno
[2] ”,Biología Molecular
[3] Hospital General Universitario “Gregorio Marañón,Unidad de Investigacion
[4] ”,Departmento de Paediatría Infecciosa
[5] Hospital General Universitario “Gregorio Marañón,Unidad de Pediatría Infecciosa, Departmento de Pediatría
[6] ”,undefined
[7] Hospital “Virgen del Rocío,undefined
[8] ”,undefined
来源
Journal of Clinical Immunology | 2003年 / 23卷
关键词
HIV; viral load; children; T-cell subsets; TRECs;
D O I
暂无
中图分类号
学科分类号
摘要
Thirty two HIV-infected children, on highly active antiretroviral therapy (HAART) and >500 CD4+ T cells/mm3, were rated according to the time-course of viral load (VL) during the whole follow-up period (>18 months) in a longitudinal retrospective study. (a) uVL group: 15 children with VL below 400 copies/mL; (b) dVL group: 17 children with higher VL. The uVL group showed higher memory (CD4+CD45RO+) T cells than did dVL group, and higher number of memory activated CD4+CD45RO+HLA-DR+ than did control group (healthy age-matched uninfected children), whereas CD4+CD45RAhi+CD62L+ was similar. However, TCR rearrangement excision circles (TRECs) were higher in uVL group than in dVL group. uVL Group showed CD8+CD45RO+ and CD8+CD45RO+CD38+ higher number than the control group, but lower than the dVL group. The percentage of CD8+CD45RAhi+CD62L+, CD8+CD45RA+, CD8+CD62L+, and CD8+CD28+ was higher in uVL group than in dVL group, and lower than in control group. The uVL group showed higher number of activated (HLA-DR+CD38+, HLA-DR+, HLA-DR+CD38−) CD4+ T cells and lower percentages of CD4+HLA-DR−CD38+ than dVL group. In activated CD8+ T cell, the uVL group had lower CD8+HLA-DR+CD38+, CD8+HLA-DR+, and CD8+CD38+ than the dVL group. Preeffector (CD8+CD57−CD28− and CD8+CD45RA−CD62L−) T cells were lower in the uVL group than in dVL group. In the effector (CD8+CD57+, CD8+CD57+CD28−, and CD8+CD45RA+CD62L−) T cells, HIV-infected-children had higher values than control group. HIV-infected-children who respond to HAART had TRECs reconstitution, decreased immune activation, and lower effector CD8+ T cells. Moreover, successful HAART allow the increment of activated CD4+ T cells.
引用
收藏
页码:279 / 289
页数:10
相关论文
共 542 条
[1]  
Palella FJ(1998)Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators N Engl J Med 338 853-860
[2]  
Delaney KM(1999)The changing pattern of admissions to a London hospital of patients with HIV: 1988–1997. Royal Free Centre for HIV Medicine AIDS 13 1255-1261
[3]  
Moorman AC(1999)Effect of changing antiretroviral therapy on human immunodeficiency virus viral load: Experience with fifty-four perinatally infected children Lancet 353 2240-1494
[4]  
Loveless MO(1997)Protease inhibitor therapy in children with perinatally acquired HIV infection AIDS 11 1487-606
[5]  
Fuhrer J(1999)Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages J Pediatr 134 597-788
[6]  
Satten GA(2000)Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: A multicenter study in the Netherlands. On behalf of the Dutch Study Group for Children with HIV-1 infections J Pediatr 136 780-103
[7]  
Aschman DJ(2000)Immunologic response to combination nucleoside analogue plus protease inhibitor therapy in stable antiretroviral therapy-experienced human immunodeficiency virus-infected children J Infect Dis 182 96-518
[8]  
Holmberg SD(1998)Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus Pediatr Infect Dis J 17 517-564
[9]  
Mocroft A(1998)A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection J Infect Dis 177 557-1121
[10]  
Barry S(2000)Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: Week 24 results of a randomized controlled trial—PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team AIDS Res Hum Retroviruses 16 1113-173